Logo
x

Search

Subscribe Now

Eosinophil-Driven Diseases

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

  • November 18, 2021
Insights+: The US FDA New Drug Approvals in October 2021

Insights+: The US FDA New Drug Approvals in October 2021

  • November 18, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.